Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Charles River 3Q

Preclinical Services up 6% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories

3Q Revenues: $278.7 million (flat)

3Q Earnings: $22.2 million (+17%)

YTD Revenues: $849.4 million (flat)

YTD Earnings: $79.3 million (-4%)

Comments: Research Models and Services (RMS) segment sales were $166.5 million in the quarter, down 3%. Preclinical Services (PCS) sales were $112.2 million, up 6%. Income from continuing operations for the quarter was $22.4 million, compared to $18.9 million in 3Q11.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters